title: Phosphorylated AMP-activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy.
abstract: OBJECTIVE
  The present study analyzed the expression of phosphorylated AMP-activated protein kinase (pAMPK), Fyn kinase, and pyruvate dehydrogenase kinase-1 (PDK-1) and their impact on the survival of patients with resected gastric cancer who received cisplatin-based adjuvant chemotherapy.
  
  
  METHODS
  Korean patients with stage II-IV (M0) gastric adenocarcinoma who underwent a gastrectomy with D2 lymph node resection and received a combination regimen of cisplatin and S-1 were enrolled. Immunohistochemistry was carried out to determine the expression of pAMPK, Fyn kinase, and PDK-1 in operative specimens of gastric cancer. The expression was divided into two groups according to the intensity score (negative: 0 or 1+ and positive: 2+ or 3+).
  
  
  RESULTS
  From January 2006 to July 2010, 73 tumor samples obtained from 74 patients were analyzed. Forty patients were included in the pAMPK-positive group, while 33 patients were included in the pAMPK-negative group. Meanwhile, positive Fyn kinase expression was observed in only 10 patients (13.7 %), and there was no or very weak PDK-1 staining. The clinicopathologic characteristics were similar between the two groups according to the expression of pAMPK. With a median follow-up duration of 26.5 months (2.6-73.2), the estimated 3-year relapse-free survival (RFS) and overall survival rates were 55.0 and 78.4 %, respectively. In a multivariate analysis adjusted for age, sex, Lauren classification, and stage, the pAMPK-negative group was significantly associated with improved RFS (Hazard ratio = 0.459, 95 % CI 0.109-0.711, P = 0.043).
  
  
  CONCLUSIONS
  A low expression of pAMPK was found to be correlated with better RFS in patients with resected gastric cancer treated with adjuvant cisplatin-based chemotherapy.
authors.affiliation: Department of Hematology/Oncology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 807 Hogukno, Buk-gu, Daegu, South Korea.
authors.forename: Byung Woog
authors.initials: BW
authors.lastname: Kang
authors.forename: Ji Yun
authors.initials: JY
authors.lastname: Jeong
authors.forename: Yee Soo
authors.initials: YS
authors.lastname: Chae
authors.forename: Soo Jung
authors.initials: SJ
authors.lastname: Lee
authors.forename: Yoo Jin
authors.initials: YJ
authors.lastname: Lee
authors.forename: Jun Young
authors.initials: JY
authors.lastname: Choi
authors.forename: In-Kyu
authors.initials: IK
authors.lastname: Lee
authors.forename: Seong Woo
authors.initials: SW
authors.lastname: Jeon
authors.forename: Han Ik
authors.initials: HI
authors.lastname: Bae
authors.forename: Da Keun
authors.initials: DK
authors.lastname: Lee
authors.forename: Oh-Kyoung
authors.initials: OK
authors.lastname: Kwon
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Chung
authors.forename: Wansik
authors.initials: W
authors.lastname: Yu
authors.forename: Jong Gwang
authors.initials: JG
authors.lastname: Kim
mesh_terms: D055372:AMP-Activated Protein Kinases / Q000235:genetics*; D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044466:Asian People; D017024:Chemotherapy, Adjuvant / Q000379:methods; D002945:Cisplatin / Q000008:administration & dosage; D018572:Disease-Free Survival; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007723:Korea; D008197:Lymph Node Excision; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage; D010766:Phosphorylation; D010865:Pilot Projects; D011379:Prognosis; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D055372:AMP-Activated Protein Kinases; D002945:Cisplatin